Japanese clinicians have reported five cases of pyoderma gangrenosum emerging in patients treated with brodalumab for palmoplantar pustulosis, according to a case series. The IL-17 receptor A antibody has already shown efficacy for the underlying dermatologic condition in Japan, with approval based on a phase 3 program and an open-label extension. All five reported patients were women aged 40 to 70, with symptom onset occurring between 61 and 345 days after starting brodalumab. The authors frame the events as paradoxical neutrophilic dermatoses associated with IL-17 pathway inhibition, highlighting a need for heightened vigilance and differential diagnosis when new ulcerative or neutrophilic lesions develop on treatment.
Get the Daily Brief